Bank of Hawaii lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 95,305 shares of the company’s stock after selling 2,502 shares during the period. Johnson & Johnson accounts for approximately 1.0% of Bank of Hawaii’s portfolio, making the stock its 20th largest position. Bank of Hawaii’s holdings in Johnson & Johnson were worth $11,564,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. BlackRock Inc. increased its stake in shares of Johnson & Johnson by 4.7% in the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after acquiring an additional 7,853,141 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Johnson & Johnson by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock valued at $3,676,999,000 after acquiring an additional 541,338 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Johnson & Johnson by 3.8% in the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock valued at $1,591,811,000 after acquiring an additional 478,982 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock valued at $1,089,415,000 after acquiring an additional 387,504 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Johnson & Johnson by 9.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock valued at $967,793,000 after purchasing an additional 654,350 shares in the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.
Shares of JNJ stock opened at $145.85 on Friday. The firm has a market cap of $384.25 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 2.24 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.75.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. Johnson & Johnson’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.90 EPS. Analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is 49.32%.
A number of brokerages have commented on JNJ. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Raymond James boosted their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Citigroup boosted their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target for the company in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $143.47.
In other Johnson & Johnson news, EVP Michael E. Sneed sold 30,943 shares of Johnson & Johnson stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the transaction, the executive vice president now directly owns 70,817 shares of the company’s stock, valued at approximately $10,088,589.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joaquin Duato sold 40,000 shares of Johnson & Johnson stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now directly owns 112,848 shares in the company, valued at $16,290,737.28. The disclosure for this sale can be found here. Insiders have sold a total of 351,748 shares of company stock worth $51,092,647 over the last ninety days. Insiders own 0.22% of the company’s stock.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/30/johnson-johnson-jnj-stake-lessened-by-bank-of-hawaii.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Diversification in Investing
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.